Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

scientific article

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1378/CHEST.113.3.723
P698PubMed publication ID9515850
P5875ResearchGate publication ID51312388

P2093author name stringSuzuki Y
Green MR
Vogelzang NJ
Corson JM
Chahinian AP
Herndon JE
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectleukemiaQ29496
patientQ181600
P304page(s)723-731
P577publication date1998-03-01
P1433published inChestQ5093377
P1476titleFactors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
P478volume113

Reverse relations

cites work (P2860)
Q44649986A Multicenter Phase II Study of Gemcitabine and Oxaliplatin for Malignant Pleural Mesothelioma
Q51643878A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Q33341861A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma
Q34278435A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice
Q38888134Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients.
Q37070229Advances in the systemic therapy of malignant pleural mesothelioma
Q33813008An epigenetic mechanism for capecitabine resistance in mesothelioma
Q36643416Angiogenesis is an independent prognostic factor in malignant mesothelioma
Q36027639Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma?
Q51980244Automated matching of temporally sequential CT sections.
Q38660038Biomarkers and prognostic factors for malignant pleural mesothelioma
Q28387194Biomarkers and prognostic factors for mesothelioma
Q37335377Biomarkers for malignant pleural mesothelioma: current status
Q41086929Brain metastases in malignant pleural mesothelioma
Q38119922Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.
Q64235291Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP)
Q44244488Characteristics of Malignant Pleural Mesothelioma in Women
Q35141369Chemotherapy and targeted therapies for unresectable malignant mesothelioma
Q36022779Chemotherapy options and new advances in malignant pleural mesothelioma
Q52672893Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.
Q53251663Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma.
Q36755228Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
Q50050310Clinical and biologic prognostic factors in malignant pleural mesothelioma
Q36643797Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma
Q86128168Clinical and pathological features are still the best determinants of prognosis in mesothelioma
Q36723787Clinical significance of serum CA125 in diffuse malignant mesothelioma
Q41522440Clinical staging of malignant pleural mesothelioma: current perspectives
Q34239292Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
Q37029331Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma
Q37086026Current concepts in malignant pleural mesothelioma.
Q40568933Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells
Q52685808Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis.
Q39434249Diagnosis and prognosis-review of biomarkers for mesothelioma.
Q55463329Differential effects of tumor-platelet interaction in vitro and in vivo in glioblastoma.
Q35578007Diffuse Malignant Pleural Mesothelioma: Part II. Symptom Management
Q36702389Disease volumes as a marker for patient response in malignant pleural mesothelioma.
Q36140968Distinctive clinical characteristics of malignant mesothelioma in young patients.
Q36694116Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
Q36758593Emerging drugs for mesothelioma
Q46548604Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
Q37214250Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma
Q38437441Expression of bcl-2 family members in malignant pleural mesothelioma
Q63413185Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival.
Q35678085Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales
Q33914000Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma
Q37449036Future developments in the management of malignant pleural mesothelioma
Q31878746Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.
Q28394028Guidelines for the diagnosis and treatment of malignant pleural mesothelioma
Q33339509High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.
Q40804584High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.
Q40684793Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma
Q62392158Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma
Q98735838Identification of a Five-Gene Signature for Predicting Survival in Malignant Pleural Mesothelioma Patients
Q33877584Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
Q51613280Individualised management of malignant pleural effusion.
Q39818881Individualizing Mesothelioma Treatment: Small Steps Into a Brighter Future
Q37090789Inflammation in malignant mesothelioma - friend or foe?
Q56976088Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
Q74172131Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro
Q44173242Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
Q35623638Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy.
Q82051649Malignant Pleural Mesothelioma: A Population-Based Study of Survival
Q52610273Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?
Q37261327Malignant mesothelioma after household exposure to asbestos
Q47098675Malignant mesothelioma: Canadian perspective and research directions
Q74267166Malignant pleural mesothelioma
Q83412919Malignant pleural mesothelioma
Q83466825Malignant pleural mesothelioma
Q36766690Malignant pleural mesothelioma in a 17-year old boy: A case report and literature review.
Q35740408Malignant pleural mesothelioma--an update
Q40041012Malignant pleural mesothelioma: A retrospective analysis of clinicopathological and survival data.
Q33686248Malignant pleural mesothelioma: a single-center experience in Turkey
Q55113818Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
Q38019747Malignant pleural mesothelioma: from the bench to the bedside.
Q33871571Malignant pleural mesothelioma: predictors and staging
Q37277451Management of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging : Consensus of the Austrian Mesothelioma Interest Group (AMIG).
Q36830116Management options for malignant pleural mesothelioma: clinical and cost considerations
Q38308730Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura
Q51996240Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques.
Q37866663Medical treatment of mesothelioma: anything new?
Q37201356Mesothelioma and asbestos-related pleural diseases
Q35511541MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.
Q42548512Microenvironment-Dependent Phenotypic Changes in a SCID Mouse Model for Malignant Mesothelioma
Q29248127Modern management of malignant pleural mesothelioma
Q36097706Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma
Q36643866Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
Q43466291Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients.
Q35042668New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials
Q36780582Newer issues in mesothelioma chemotherapy.
Q36905239Optimising survival in malignant mesothelioma
Q26825427Paraneoplastic thrombocytosis: the secrets of tumor self-promotion
Q35782906Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma
Q24243222Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma
Q33379936Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
Q34678683Peritoneal mesothelioma
Q39831596Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure
Q39977787Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma
Q44874991Pleural mesothelioma: experience with 62 cases in 9 years
Q36287976Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies
Q34608340Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score.
Q35870489Preoperative thrombocytosis predicts poor survival in patients with glioblastoma.
Q28359542Pretreatment elevated serum lactate dehydrogenase as a significant prognostic factor in malignant mesothelioma: A meta-analysis
Q54691246Pretreatment thrombocytosis as a significant prognostic factor in malignant mesothelioma: a meta-analysis.
Q42373344Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.
Q24679305Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
Q33918135Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey
Q43875251Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma
Q33390251Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas
Q37426353Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma
Q89759390Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma
Q42000248Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma
Q78192009Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma
Q45020726Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
Q37090803Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?
Q37307815Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma
Q36425940Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma
Q33227741Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase
Q92591513Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy
Q37290519Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.
Q45740888Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma
Q44080402Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis
Q34041728Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.
Q53733133Survival and Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Study of 314 patients in the West Part of Japan
Q38607308Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response
Q50286398Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors.
Q93380858Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
Q51114246The clinicopathological characteristics with long-term outcomes in malignant mesothelioma.
Q34558970The role of SV40 in malignant mesothelioma and other human malignancies
Q33658554The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy
Q47809790The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma
Q43595658The value of inflammatory parameters in the prognosis of malignant mesothelioma
Q53320850Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
Q37301691Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B.
Q44681845Treatment and survival analyses of malignant mesothelioma in Japan
Q79267484Tumor Necrosis Correlates With Angiogenesis and Is a Predictor of Poor Prognosis in Malignant Mesothelioma *
Q26853099Tumor-platelet interaction in solid tumors
Q36986796Unusual presentation and location pleural malignant mesothelioma
Q38758684Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
Q36652941Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
Q39434239Volumetric assessment in malignant pleural mesothelioma
Q37128016Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy?
Q35172562Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma
Q82061962[Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma]
Q53893407[Malignant mesothelioma--a diagnostic challenge].
Q80352857[Malignant pleural mesothelioma: radiotherapy for the prevention of seeding nodules]
Q38451233c-Kit is not expressed in malignant mesothelioma
Q40466065miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma.

Search more.